Phase I/II study of docetaxel/CDGP/5-FU for advanced or recurrent esophageal cancer
Not Applicable
- Conditions
- Esophageal cancer
- Registration Number
- JPRN-UMIN000014462
- Lead Sponsor
- Tokushima University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
(1) history of drug hypersensitivity. (2) active concomitant malignancy. (3) serious complications (severe heart disease, active infection) (4) pregnant or lactating females. (5) The investigator considers not suitable for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase I To determine the recommended dose (RD) Phase II Safety, Tumor responses
- Secondary Outcome Measures
Name Time Method